Trial aims to extend remission for children treated with T-cell immunotherapy for leukemia

(Seattle Children's) After phase 1 results of Seattle Children's Pediatric Leukemia Adoptive Therapy (PLAT-02) trial have shown T-cell immunotherapy to be effective in getting 93 percent of patients with relapsed or refractory acute lymphoblastic leukemia into complete initial remission, researchers have now opened a first-in-human clinical trial aimed at reducing the rate of relapse after the therapy, which is about 50 percent.
Source: EurekAlert! - Biology - Category: Biology Source Type: news